MAP2K7 and melanoma: The aim of the current study was to utilize a diverse melanoma cell line panel (n = 31) of known mutational status (BRAF, HRAS, NRAS, and phosphatase and tensin homolog (PTEN)) to aid in the identification of a patient population most likely to respond to MEK inhibition.